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Immune interferenceLittle is known about the inﬂuences of other porcine circovirus type 2 (PCV2) proteins on the
immunogenicity of Cap protein. Here we constructed plasmids expressing the ORF1 (pORF1) and ORF3
(pORF3) of PCV2, and mixed either of them with the plasmid expressing ORF2 (pORF2) as combined DNA
vaccines, to compare their immunogenicity and protective efﬁcacy. Our data revealed that pORF1 reduced
the Cap-speciﬁc CD8+cell frequency, and both pORF1 and pORF3 attenuated the Cap-speciﬁc Th1 and post-
challenge-recall VN antibody responses induced by the pORF2 plasmid, despite successful induction of Rep
and ORF3 antibodies by pORF1 and pORF3, respectively. Subsequently, protocols with pORF1 or pORF3
showed signiﬁcantly decreased protective efﬁcacy compared to pORF2 alone. Overall, our data suggested
that the ORF1- and ORF3-encoded Rep and ORF3 proteins may interfere with the cellular, humoral and
protective immunity of the ORF2-encoded Cap protein in vivo.
© 2009 Elsevier Inc. All rights reserved.IntroductionPorcine circovirus (PCV) is a nonenveloped, single-stranded,
circular DNA virus with a diameter of 17 nm (Tischer et al., 1982).
PCV was ﬁrst discovered as a noncytopathic contaminant of the
porcine kidney cell culture PK-15 (Tischer et al., 1974). The PK-15-
derived PCV, designated PCV1, did not produce clinical disease in
experimentally inoculated pigs and was considered to be nonpatho-
genic (Allan et al., 1995; Tischer et al., 1986). In contrast, PCV2 was
identiﬁed as the primary etiological agent of an emerging disease in
1991, named postweaning multisystemic wasting syndrome (PMWS)
(Allan et al., 1998; Allan and Ellis, 2000; Clark, 1997). PMWS is
considered an important swine disease and has had a serious
economic impact on the global swine industry. This disease affects
pigs from 5 to 12 weeks of age, with 5–30%morbidity. Clinical signs of
the disease include progressive weight loss, difﬁcult breathing,
dyspnea, and jaundice (Clark, 1997). In addition to PMWS, PCV2 is
also associated with pneumonia, enteritis, reproductive failure,
porcine dermatitis and nephropathy syndrome (PDNS) and a variety
of other manifestations (Opriessnig et al., 2007).
The complete genomic sequences of PCV1 and PCV2 have been
determined (Hamel et al., 1998; Meehan et al., 1997, 1998; Zhou et
al., 2006). The overall DNA sequence homology within PCV1 or PCV2mal Epidemic Etiology and
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PCV2 isolates is 68 to 76%. PCV2 possesses 3 conﬁrmed ORFs: ORF1
located on the viral plus-strand, ORF2 and ORF3 on the counter-
clockwise strand, with lengths of 945, 702 and 315 nts, respectively.
PCV2 ORF1 encodes a 35.7 kDa replication protein (Rep) involved in
virus replication (Mankertz et al., 1998). PCV2 ORF2 encodes a
27.8 kDa capsid protein (Cap) involved in viral immunogenicity
(Mahe et al., 2000; Nawagitgul et al., 2000; Truong et al., 2001).
PCV2 ORF3 protein is not essential for PCV2 replication, but involved
in PCV2-induced apoptosis (Liu et al., 2005).
As the primary immunorelevant protein, PCV2 Cap protein
expressed in insect cells (Nawagitgul et al., 2000) or Escherichia
coli (Zhou et al., 2005a) could be detected by sera of pigs
experimentally infected with PCV2. In addition, multiple immuno-
reactive regions (Mahe et al., 2000) and epitopes (Lekcharoensuk
et al., 2004; Shang et al., 2009) have been identiﬁed. Monoclonal
antibodies against Cap protein show neutralizing activity against
PCV2 (McNeilly et al., 2001; Zhou et al., 2005a), suggesting the
protein contains at least 1 neutralizing epitope on the virus. In
contrast to Cap, limited information is available on the immuno-
genicity of Rep and ORF3 proteins. Utilizing PEPSCAN analysis, one
immunoreactive area (aa 185–211) was identiﬁed in PCV2 Rep
protein (Mahe et al., 2000). In another study, 2 immunoreactive T
lymphocyte epitopes in Rep protein (aa 81–100 and aa 201–220)
and 1 in ORF3 protein (aa 31–50) were demonstrated (Stevenson
et al., 2007).
PCV2 Cap protein has been studied intensely as vaccine antigen
due to its excellent immunogenicity (Blanchard et al., 2003; Fan et al.,
Table 1
PCV2 Cap-speciﬁc lymphoproliferative response and FCM analysis of mice splenocytes.
Group SI Immunophenotypic cells
CD4+ (%) CD8+ (%)
pORF2 + pCI 1.54±0.32a 15.80±0.67a 14.94±2.56a
pORF2 + pORF1 1.38±0.13a 14.00±2.87a 11.58±2.41b
pORF2 + pORF3 1.36±0.20a 13.07±1.75a 12.08±1.83a,b
DNA control 1.00±0.00b 9.40±3.80b 11.63±2.17b
a, bDifferent superscripts within columns represent signiﬁcant differences between
groups (Pb0.05).
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Wang et al., 2006). By using ORF2-based DNA and subunit vaccines in
mice, we previously demonstrated that Cap-speciﬁc CD8+ T cells
and virus-neutralizing (VN) antibody correlating mainly with IgG2a
play crucial roles in protective immunity against PCV2 (Shen et al.,
2008). In contrast, Rep and ORF3 proteins are generally considered
weakly immunogenic and seldom used as vaccine antigens. At this
time, their immunorelavent characteristics in vivo remain unclear.
Since Rep or ORF3 antigens alone may be insufﬁcient to provide
adequate immunity against PCV2, combining them with Cap would
be an alternative approach to examine their effects on viral
immunogenicity. Based on this hypothesis, using a mixed DNA
vaccine strategy, we investigated the inﬂuences of ORF1 and ORF3
plasmids on the immunogenicity of the ORF2 plasmid. Our results
suggest that ORF1 or ORF3 DNA vaccines reduce the immunogenic
properties and efﬁcacy of ORF2 DNA vaccines. Our data help
elucidate the effect PCV2 Rep and ORF3 proteins play in the onset
of immunity in the host.
Results
In vitro expression of mammalian expression vector
Recombinant plasmids expressing PCV2 ORF1 and ORF3 were
constructed for use as DNA vaccines. Plasmids were conﬁrmed by
PCR, restriction enzyme digestion, and DNA sequencing. In vitro
expression of protein was analyzed by transient transfection
followed by immunoperoxidase monolayer assay (IPMA). When
detected with swine PCV2-positive serum, strong signals in
pORF1-transfected cells but lacking in pORF3-transfected cells
were observed (Fig. 1). However, both of the expressed proteins,
localized in nuclei of transfected cells, reacted strongly with the
Rep or ORF3 antisera respectively (Fig. 1). As controls, signals
were not observed in cells transfected with pCI-neo vector
(Fig. 1). The results indicate that the recombinant vectors, pORF1
and pORF3, may express the Rep and ORF3 proteins respectively
in vivo.Fig. 1. Expression of PCV2 Rep and ORF3 proteins in vitro. PCV-free PK-15 cells were transfect
The plasmid and antibody (in parentheses) used for each transfection and detection are ind
anti-Rep, rabbit anti-ORF3, and swine anti-PCV2 sera separately.Cap-speciﬁc cellular immune responses
The Cap-speciﬁc lymphoproliferative responses, CD4+ and CD8+
cell frequencies of vaccinatedmice were determined and compared at
8 weeks post the ﬁrst immunization (p.i.). As shown in Table 1,
splenocytes from all the vaccine groups showed proliferative
responses when compared to the control mice, with greater statistical
difference in pORF2 + pCI group (Pb0.01) than the pORF2 + pORF1
(Pb0.05) and pORF2 + pORF3 (Pb0.05) groups. For ﬂow cytometric
analysis, compared with the control group, signiﬁcantly higher
proportions of CD4+ cells were observed in pORF2 + pCI (Pb0.01),
pORF2 + pORF1 (Pb0.01) and pORF2 + pORF3 (Pb0.05) groups;
however, in the case of CD8+ cells, only the pORF2 + pCI group had a
signiﬁcantly higher frequency than the control (Pb0.05) (Table 1).
Comparing among the vaccine groups, the CD8+ cells in pORF2+
pORF1 group was signiﬁcantly lower than that in pORF2+ pCI group
(Pb0.05), suggesting a suppressive effect of pORF1 plasmid to the
Cap-speciﬁc CD8+ cell frequency induced by the pORF2 plasmid.
Total IgG antibody response to PCV2 Cap protein
Total IgG antibody titers against Cap protein were compared
among groups. Plasmids pORF2 + pCI elicited the highest antibody
response at 4–16 weeks p.i., with the peak IgG titer of 11.2±1.3
log2 at 12 weeks (Fig. 2A). As for the co-administration groups, the
combined use of pORF1 and pORF3 induced peak titers of 5.6±3.8ed with pORF1, pORF3 or pCI-neo, ﬁxed at 48 h post-transfection, and detected by IPMA.
icated on top of each panel; cells transfected with pCI-neo were detected with mouse
Fig. 2. Kinetics of total IgG (A) and IgG isotypes (B) against Cap protein at various times p.i. or p.c. The IgG, IgG1 and IgG2a titers were measured by indirect ELISA. Error bars show the
standard deviations (n=5). The letters ‘a’ and ‘b’ above columns indicate a signiﬁcantly higher IgG isotype with values of Pb0.05 and Pb0.01, respectively, at the same time in a
group. Mice were challenged at 16 weeks p.i.
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(Fig. 2A). Statistically, the Cap-speciﬁc IgG in group pORF2 + pCI
were signiﬁcantly higher than that in pORF2 + pORF1 (at 12–
16 weeks) and pORF2 + pORF3 (at 10–12 weeks) groups (Pb0.05).
These data suggest that the co-administrations of pORF1 or pORF3
attenuated the Cap-speciﬁc antibody responses elicited by the
pORF2 plasmid.
IgG isotype proﬁles against PCV2 Cap protein
The different vaccination approaches can affect the antibody
isotype and T-helper (Th) cell type of an immune response; IgG2a is
produced as a consequence of Th1-cell activation, whereas Th2-cell
activation enhances the production of IgG1 and suppresses IgG2a
(Mosmann and Coffman, 1989). To better understand the types of
immune responses, we examined the IgG isotype proﬁles against Cap
protein. In general, vaccinated mice developed higher IgG2a titers
than IgG1, with signiﬁcant differences in pORF2+ pCI (at 8–16 weeks
p.i.) and pORF2+ pORF3 (at 6–10 and 14 weeks p.i.) groups (Pb0.05)(Fig. 2B), suggesting a Th1 immune response during the corres-
ponding period. Following challenge, titers of IgG1 and IgG2a
increased to varying levels in all groups, but the isotype proﬁles
remained similar to that prior to challenge. Interestingly, no anti-Cap
IgG1 antibodies were detected in pORF2 + pORF1 vaccinated mice
even after the PCV2 challenge; however, the non-signiﬁcant diffe-
rences between IgG1 and IgG2a titers revealed a non-biased Th
response in this group. Overall, our data suggest that the pORF1 and
pORF3 plasmids shorten the duration of Th1 responses induced by
pORF2.
Total IgG and isotype proﬁles to PCV2 Rep and ORF3 proteins
The total IgG and isotype proﬁles against PCV2 Rep or ORF3
proteins were detected in the corresponding groups. As shown in
Fig. 3A, low levels of anti-Rep IgG were detected in mice of pORF2 +
pORF1 group, with a peak titer of 6.0±3.3 log2 at 16 weeks p.i.
Following challenge, control mice also developed Rep-speciﬁc IgG,
with a peak titer of 6.8±2.7 at 4 weeks post challenge (p.c.). The anti-
Fig. 3. Kinetics of antibody responses to PCV2 Rep and ORF3 proteins induced by different vaccine combinations. The total IgG levels against Rep (A) and ORF3 (B) proteins, and the
IgG isotypes speciﬁc for Rep (C) and ORF3 (D) proteins are shown for each group. The IgG, IgG1 and IgG2a titers were measured by indirect ELISA. Error bars show the standard
deviations (n=5). The letter ‘a’ above column indicates a signiﬁcantly higher IgG isotype (Pb0.05) at the same time in a group. Mice were challenged at 16 weeks p.i.
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16 weeks p.i. in pORF2 + pORF3 vaccinated mice, whereas titers as
low as 4.6–5.0 log2 were detected in control mice at 2 to 6 weeks p.c.
(Fig. 3B). Antibody isotype analysis revealed that, except for the anti-
Rep IgG1 in pORF2 + pORF1 group which were signiﬁcantly higher
than IgG2a at 4 to 6 weeks following challenge, no signiﬁcant diffe-
rences between IgG1 and IgG2a against Rep or ORF3 proteins were
observed, suggesting a non-biased Th response to Rep or ORF3
following immunization in both groups (Figs. 3C–D).Table 2
Neutralizing antibody titers of themice immunizedwith different vaccine combinations.
Group No. of mice with VN antibody/no. detected
(mean VN titer±SD) at weeks p.c.a
2 4 6
pORF2 + pCI 3/5 (320±320)b 5/5 (456±527)b 5/5 (648±630)b
pORF2 + pORF1 0/5 (0)c 3/5 (12±11)c 3/5 (48±44)c
pORF2 + pORF3 0/5 (0)c 0/5 (0)c 0/5 (0)c
DNA control 0/5 (0)c 1/5 (4±9)c 2/5 (8±11)c
aVN titers are expressed as the maximum serum dilution yielding a 70% reduction in
ﬂuorescent focus number. Mice with VN titers ≥20 were considered positive. “0” value
is equal to “b20”.
b, cDifferent superscripts within columns represent signiﬁcant differences between
groups for each week p.c. (Pb0.05).VN antibody responses to PCV2
The ability of mouse sera to neutralize PCV2 infection was
detected by VNT in parallel with the ELISA test. Prior to virus
challenge, there were no detectable neutralizing antibodies in any
group (data not shown). After challenge with the PCV2 strain HZ0201
at 16 weeks p.i., strong anamnestic VN antibody responses were
observed in pORF2 + pCI group, which increased steadily peaking at
6 weeks p.c. (Table 2). In contrast, mice in pORF2 + pORF1, pORF2 +
pORF3 and control groups exhibited weak recall VN antibody
responses. Statistically, pORF2 + pCI group showed signiﬁcantly
higher VN titers than pORF2 + pORF1 and pORF2 + pORF3 groups
throughout the entire post-challenge period (Pb0.05) (Table 2).
These results suggest that the combined use of pORF1 or pORF3
markedly attenuated the pORF2-primed recall VN antibody responses
following PCV2 infection.
Protection from PCV2 challenge
No clinical signs or gross lesions were observed in the challenge
control group. Microscopic lesions included lymphocyte depletion
and inﬁltration of histiocytes in splenic follicles as described
previously (Shen et al., 2008). In the unchallenged control group, no
abnormal follicles were found in the spleen at 6 weeks p.c. (Fig. 4).
Fig. 4. Frequencies of abnormal spleen follicles at 6 weeks p.c. Same letter above
columns indicates no signiﬁcant difference (PN0.05); different letters indicate
signiﬁcant differences among the groups (Pb0.05) (n=5).
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had the lowest lesion frequency (14.6±6.4%) and showed a
signiﬁcant difference with the challenged control mice (38.7±5.9%)
(Pb0.01) (Fig. 4). However, plasmid mixtures of pORF2 + pORF1 and
pORF2 + pORF3 demonstrated similar lesion frequencies to that of
the challenge control group.
Further, we quantiﬁed the PCV2 DNA in serum of challenged mice
using real-time PCR. Following PCV2-inoculation, all mice in pORF2+
pORF3 and control groups were positive for PCV2 DNA at 2, 4, and
6 weeks p.c. Fewer mice in the pORF2 + pCI and pORF2 + pORF1
groups were positive for PCV2 DNA throughout the post challenge
period except the pORF2 + pORF1 group at 4 weeks p.c. (Table 3).
Compared with the challenge control mice, PCV2 DNA copy numbers
in pORF2 + pCI group were signiﬁcantly lower at 2–6 weeks p.c.
(Pb0.05), whereas those in pORF2 + pORF1 and pORF2 + pORF3
groups were lower at 2–4 weeks and 4 weeks p.c. (Pb0.05),
respectively (Table 3).
Discussion
The ORF1 is the largest ORF of PCV2 and encodes the Rep protein,
in which three domains typical for enzymes initiating replication in
the rolling circle mode have been identiﬁed as well as a P-loop for
dNTP-binding (Mankertz et al., 1998). Besides the full-length protein
Rep, a spliced isoform of the replication protein called Rep′ has also
been identiﬁed (Mankertz and Hillenbrand, 2001). Both the Rep and
Rep′ proteins are essential for PCV replication; mutations in either Rep
or Rep′ proteins resulted in N99% reduction of viral protein synthesis
and complete shutdown of viral DNA replication (Cheung, 2003;
Mankertz and Hillenbrand, 2001). Small interfering RNAs (siRNAs)
targeting PCV ORF1 inhibit viral RNA and DNA replication as well as
protein synthesis in PK-15 cells (Feng et al., 2008; Sun et al., 2007),
and combined use of siRNAs against both ORF1 and ORF2 showed a
synergistic effect (Feng et al., 2008). However, Rep protein is weakly
immunogenic compared to the Cap protein, and exhibits a reducedTable 3
Viremia in mouse serum measured by quantitative PCR.
Group No. of mice with viremia / no. detected
(mean log PCV2 load±SD) at weeks p.c.
2 4 6
pORF2 + pCI 2/5 (5.8±5.1)a 2/5 (5.6±4.9)a 1/5 (3.7±3.0)a
pORF2 + pORF1 2/5 (5.2±4.4)a 5/5 (7.2±6.2)a 3/5 (5.5±4.5)a,b
pORF2 + pORF3 5/5 (6.9±5.8)b 5/5 (7.0±6.0)a 5/5 (5.9±4.8)a,b
DNA control 5/5 (6.9±5.8)b 5/5 (7.7±6.6)b 5/5 (6.2±5.4)b
a, bDifferent superscripts within columns represent signiﬁcantly different PCV2 loads
(copies/ml) for each week p.c. (Pb0.05). “0” value is equal to “b103 copies/ml” (the
threshold of sensitivity of the quantitative PCR).effect on the Cap vaccine efﬁcacy when co-administered to pigs
(Blanchard et al., 2003). In recombinant pseudorabies virus systems,
Rep-Cap fusion protein failed to (Ju et al., 2005) but Cap alone
successfully (Song et al., 2007) induced speciﬁc antibody responses,
suggesting that the Rep in Rep-Cap fusion antigen has a suppressive
effect. In the present study, our data suggest that pORF1 decreased the
Cap-speciﬁc immune responses induced by pORF2, as evidenced by
the reduced Cap-speciﬁc CD8+ cell frequency and IgG1 antibody
production, and weak protection efﬁcacy in pORF2 + pORF1 group.
Similar to ORF1, we found that the co-administration of pORF3 also
reduced the Cap-speciﬁc antibody response induced by pORF2
plasmid.
Mixed DNA vaccination is an ideal strategy to investigate the
immunogenicity of their encoded proteins. Immunization with
mixtures of DNA vaccines could induce enhanced or comparable
immune responses compared to the single plasmid, which has been
demonstrated in the models of malarial (Grifantini et al., 1998),
pseudorabies virus (van Rooij et al., 1998), mycobacterium tubercu-
losis (Morris et al., 2000), and Plasmodium falciparum (Jones et al.,
2002). On the other hand, in some studies the mixed DNA vaccine led
to a decreased response compared to the individual component
(Sedegah et al., 2004; Wang et al., 2007). The immune suppression is
thought to be caused by antigenic competition that occurs during
uptake by the host cells, or competition within cells for translation
factors or apparatus, or competition in the antigen processing
pathway (Sedegah et al., 2004). However, the attenuation effects of
pORF1 and pORF3 plasmids on pORF2 may be closely associated with
the pathogenicity roles of their encoded proteins.
It is generally accepted that PCV2 induces immunosuppression in
pigs. Flow cytometric analysis in PBMCs revealed decreased CD4+ and
IgM+ cells (B lymphocytes) (Segales et al., 2001), or decreased CD8+
and IgM+ cells (Darwich et al., 2003) in naturally PMWS affected pigs.
A decrease in IgM+ and CD8+ cells is also found to correlate with the
quantity of PCV2 DNA in lymphoid tissues (Darwich et al., 2002).
Similar results in PCV2 experimental infections have shown decreased
levels of CD4+CD8+, CD4+CD8−, and CD4−CD8+ T cells in PCV2-
inoculated pigs (Nielsen et al., 2003). Currently little is known
regarding the viral proteins by which the PCV2 infection may result in
immunosuppression. In the present study, the plasmid-encoded Rep
protein decreased the Cap speciﬁc CD8+ cells, and both Rep and ORF3
proteins inhibited the Cap speciﬁc antibody production, suggesting an
immunosuppressive role of these 2 proteins. Since the Rep has also
shown suppression of Cap in a mixed subunit vaccine strategy
(Blanchard et al., 2003), it is likely that the antigenic competition may
occur in the antigen processing or presenting pathways. Also, the
pathogenic role of ORF3 protein in vivo (Liu et al., 2006) may
contribute to its suppression of Cap speciﬁc immunity. Since the
pORF1 and pORF3 plasmids interfered with the onset of immunity of
pORF2 plasmid, the Rep or ORF3 proteins produced during PCV2
infection may also suppress the development of Cap-speciﬁc
immunity resulting in decreased protection in the host.
A strong Cap speciﬁc Th1 immune response is important for
protective immunity against PCV2 infection (Shen et al., 2008). IgG
isotype proﬁles were therefore investigated in this study to assess the
inﬂuences of Rep or ORF3 proteins on the nature of the immune
responses against Cap protein. The duration of the vaccine-induced
Th1 response against Cap protein was totally abrogated in pORF2 +
pORF1 group, and truncated in pORF2 + pORF3 group. In a recent
study, ORF1 plasmid immunization elevated IFN-γ and IL-13 on 35 DPI
(An et al., 2008). Although IFN-γ is a Th1 cytokine, its activity has been
shown to prevent the outgrowth of Th2 cells rather than to promote
Thl cells (Seder et al., 1992). IL-13, as a Th2 cytokine, may antagonize
the macrophage-activating actions of IFN-γ (London et al., 1998).
Therefore, the disturbance of cytokine production may be related to
the abrogation of Cap speciﬁc Th1 immune response in pORF2 +
pORF1 group. In the case of ORF3 plasmid, its inoculation in high dose
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(An et al., 2008). The impaired IL-12 level may affect the development
of a Th1 immune response, since IL-12 is thought to directly augment
Thl differentiation during Th cell priming (Seder et al., 1993). Further,
the elevated pro-inﬂammatory cytokine TNF-α, clinical signs, and
lethal rate (9/15) observed in ORF3 plasmid inoculated mice in the
above study (An et al., 2008) demonstrated the pathogenic role of
ORF3 protein in vivo, which may also account for the weak Cap-
speciﬁc Thl immunity observed in pORF2 + pORF3 group.
It has been shown that PCV2 vaccines are an effective tool to
reduce losses in swine herds caused by PCV2-associated disease.
Currently there are several types of antigens available in commercial
vaccines, including PCV2 expressed in a killed baculovirus vector, an
inactivated PCV2 virus, a killed chimeric PCV1–2 virus, and Cap
protein expressed in a baculovirus system (Opriessnig et al., 2007).
According to our data, the Rep and ORF3 proteins presented in the ﬁrst
three vaccines may interfere with the Cap-induced protective
immunity against PCV2 infection. However, it should be pointed out
that Rep and ORF3 proteins may be overexpressed in our study, and
the expression abundance of ORF1, 2 and 3 may not reﬂect the real
situation in a virus infection, or a virus antigen stock. Therefore, it
needs further study to investigate how great the suppressive effects of
Rep and ORF3 proteins may have in a commercial vaccine.
Overall, in the present study, we investigated the inﬂuences of the
pORF1 and pORF3 on the immunogenicity of the pORF2 by comparing
the antigen-speciﬁc cellular and humoral immune responses as well
as protective efﬁcacy. We demonstrated the suppressive effects of
plasmid-encoded Rep and ORF3 proteins on the immunogenicity of
Cap in mixed DNA vaccinations. Uncovering such interactions will
undoubtedly lead to further understanding of the immunogenicity of
PCV2, and ultimately, improved vaccines.
Materials and methods
Cells, virus, proteins, antisera and mice
A PCV-free PK-15 cell line was maintained in minimal essential
medium (MEM, Gibco, Grand Island, NY) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Gibco). The virulent PCV2
isolate HZ0201 was originally isolated from pigs with naturally
occurring PMWS (Zhou et al., 2006) and serially passaged in PK-15
cells 15 times. PCV2 Rep and Cap proteins were generated as
described previously (Li et al., 2007; Zhou et al., 2005a). PCV2 ORF3
proteins were expressed in E. coli BL21 by recombinant pGEX-4T-1
vector (Amersham, Pharmacia Biotech AB, Uppsala, Sweden) insert-
ing PCV2 ORF3 (unpublished data). Swine anti-PCV2 serum was
acquired from piglets experimentally infected with PCV2 isolate
HZ0201. Mouse anti-Rep and rabbit anti-ORF3 sera were obtained by
immunizing animals with the prokaryotic expressed Rep and ORF3
proteins, respectively. Female BALB/c mice were purchased from
Shanghai laboratory animal center (Chinese Academy of Sciences,
Shanghai, China) and bred in automatic extrusion independent
venting isolation cages (Fengshi laboratory animal equipment Co.
Ltd., Suzhou, China).Table 4
Summary of experimental treatments.
Groups Mouse no. Immunizations LPA and FCMa
(wk 0, 2, 4)
pORF2 + pCIb 10 pORF2 and pCI-neo Mouse splenocytes we
prepared at 8 wk p.i.pORF2 + pORF1b 10 pORF2 and pORF1
pORF2 + pORF3b 10 pORF2 and pORF3
DNA controlc 15 pCI-neo
a Each treatment includes 5 mice.
b Mouse was vaccinated with 100 μg of each plasmid in 100 μl volume.
c Mouse was vaccinated with 200 μg of pCI-neo in 100 μl volume.Construction and preparation of the DNA vaccines
PCV2 ORF1 and ORF3 were ampliﬁed from the genomic DNA of
HZ0201 (GenBank accession no. AY188355) using the speciﬁc primers
as follows: forward (5′-ATAACGCGTCATGCCCAGCAAGAAG-3′) and
reverse primer (5′-GCGGTCGACGACTCAGTAATTTATTTCATATGG-3′)
for ORF1, and forward (5′-TAAGTCGACCTTACTGATGGAGTGTGG-3′)
and reverse primer (5′-ATAACGCGTATGGTAACCATCCCAC-3′) for
ORF3. The PCR products were cloned into a mammalian expression
vector pCI-neo (Promega, Madison, WI) to generate the expression
vectors pORF1 and pORF3, respectively. To determine the expression
of Rep and ORF3 proteins in vitro, PCV-free PK-15 cells were
transfected with the recombinant plasmids by Lipofectin Reagent
(Invitrogen, Carlsbad, CA). At 48 h post-transfection, cells were ﬁxed
and detected by an immunoperoxidase monolayer assay (IPMA)
(Zhou et al., 2005a) using the swine PCV2-positive serum, or the
mouse anti-Rep or rabbit anti-ORF3 sera as the primary antibodies.
Recombinant vector expressing PCV2 ORF2 (pORF2) was constructed
and conﬁrmed previously (Shen et al., 2008). Finally, the plasmids
pORF1, pORF3 and pORF2 were puriﬁed by endoFree plasmid Giga kit
columns (Qiagen, Valencia, CA) and used as DNA vaccines.
Experimental design and samples collection
All themice at 8weeks of agewere grouped randomly and injected
intramuscularly in the quadriceps with 100 μg of each plasmid in a
total of 100 μl PBS as summarized in Table 4. Mice received 3 doses of
vaccine at 2-week intervals. Mice given similar injections of 200 μg
pCI-neo (pCI) in 100 μl PBS were used as the DNA control. Five mice in
each group were euthanized for ﬂow cytometric analysis (FCM) and
lymphocyte proliferation assay (LPA) at 8 weeks p.i. At 16 weeks p.i.,
ﬁve mice of each group were challenged intraperitoneally with 0.2 ml
of PCV2 inoculum (104.75 TCID50/0.1 ml). Clinical observations were
recorded daily for 6 weeks and then all mice were euthanized and
spleens were collected for pathological analysis. Serum samples were
withdrawn from the retro-orbital sinus biweekly for antibody
detection and/or viremia evaluation.
Lymphocyte proliferation assay (LPA)
Cap-speciﬁc lymphoproliferative response of the splenocytes
from the immunized mice was determined by MTT test as described
previously (Zhou et al., 2005b). In brief, spleens were aseptically
removed from the mice at 8 weeks p.i. to make single-cell
suspensions (4×106 cells/ml) in RPMI 1640 containing 5% FBS
(RPMI1640-FBS), and applied to each well of 96-well culture plates
at 100 μl/well. Wells containing no cells were used as blank controls.
The PCV2 Cap protein diluted in RPMI1640-FBS was then added at a
ﬁnal concentration of 1 μg/ml (100 μl/well) to stimulate the
splenocytes. Cells were cultured at 37 °C in 5% CO2 for 48 h. Twenty
μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT, Sigma, St. Louis, MO) (5 mg/ml) was added to each well and
incubated for 4 h. The cells were then lysed by adding 100 μl of lysis
buffer (10% SDS, 0.01 mol/L HCl) to each well. After 20 h ofAntibody detectiona Protection assaya
re ELISA and VNT were performed
at 2-wk intervals
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570 nm. The LPA was performed in duplicate and stimulation index
(SI) was calculated from the formula: SI=(ODvaccine−ODblank)/
(ODDNA control−ODblank).
Flow cytometric analysis (FCM)
The above Cap-stimulated and cultured splenocytes were resus-
pended in 50 μl PBS (106 cells) and incubated with 50 μl diluted
(1:200) FITC-conjugated anti-mouse CD4 (L3T4) and R-PE-conjugat-
ed anti-mouse CD8α (Ly-2) monoclonal antibodies (BD Biosciences,
Mountain View, CA) at a concentration of 0.5 μg/million cells on an ice
bath. After 20 min incubation, cells were washed and analyzed on a
BDLSR cytoﬂuorimeter using the CellQuest software (BD Biosciences).
ELISA
Titers of total IgG, IgG1 and IgG2a antibodies against PCV2 Rep, Cap
and ORF3 proteins were determined by indirect ELISA. Ninety-six-
well plates (Nunc, Roskilde, Denmark) were coated with 100 μl
corresponding protein (1 μg/ml for Rep and Cap; 2 μg/ml for ORF3) in
0.05 M Tris–HCl buffer (pH8.5) and left at 4 °C overnight. Next,
blocked with PBS containing 5% skimmed dry milk, 100 μl of the
serially 2-fold diluted mouse serum samples (lowest dilution, 1:64)
were added and incubated at 37 °C for 60 min. The bound antibodies
were detected by horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG, IgG1, or IgG2a antibodies (dilution, 1:6000; Southern
Biotechnology Associates). Tetramethylbenzidine (Sigma) was used
as a chromogen for color development, and absorbance wasmeasured
at 450 nm. Antibody titers were deﬁned as the reciprocal of the
highest dilution of sample for which the ODwas at least 2 times that of
the control serum sample run on the same plate. The data were
presented as the log2 of the titer.
Virus neutralization test
Virus neutralization tests (VNT) were performed using serum
samples that were previously heat inactivated at 56 °C for 30 min.
Brieﬂy, an equal volume of 105.0 TCID50/0.1 ml PCV2 HZ0201 and the
serial 2-fold dilutions (1:20 to 1:20,480) of the sera were mixed and
incubated at 37 °C for 1 h. The serum–virus mixture was inoculated
into 96-well microtitre plates containing semi-conﬂuent monolayers
of PCV free PK-15 cells in 10 μl per well at a ratio of 1:10, using 2 wells
per serum dilution. The plate was incubated for 48 h at 37 °C. Finally,
the 96-well plates were screened by indirect immunoﬂuorescence
assay (Zhou et al., 2006). The serum titers were determined as the
reciprocal of the highest serum dilution at ≥70% ﬂuorescent focus
reduction in the infected cell cultures under a ﬂuorescent microscope.
Pathology and viremia evaluations
At 6 weeks p.c., pathological analysis and viremia evaluation were
performed as previously described (Shen et al., 2008). Lesion severity
was estimated as the frequency of abnormal spleen follicles based on
the ratio between the number of the follicles demonstrating lymphoid
depletion and histiocytic inﬁltration by the total follicles counted in
each sample of spleen. A quantitative real-time PCR method was used
for assessing viremia. PCV2 genomic copies per ml of serum were
represented as the mean value of duplicate reactions.
Statistical analysis
Data statistical analysis was performed by one-way analysis of
variance (ANOVA) using the SPSS software program version 12.0.
Results were considered to be statistically signiﬁcant when the P
value was less than 0.05.Acknowledgments
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